The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

被引：0
|
作者：
C. J. Currie
C. D. Poole
E. A. M. Gale
机构：
[1] Cardiff University,School of Medicine
[2] The Pharma Research Centre,Department of Epidemiology
[3] Cardiff MediCentre,Diabetes and Metabolism, School of Medicine
[4] Pharmatelligence,undefined
[5] Bristol University,undefined
来源：
Diabetologia | 2009年 / 52卷
关键词：
Cancer; Insulin; Insulin analogues; Metformin; Sulfonylureas; Survival; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1766 / 1777
页数：11
相关论文
共 50 条
  • [41] New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies
    Hsiao, Fu-Chih
    Yen, Kun-Chi
    Chao, Tze-Fan
    Chen, Shao-Wei
    Chan, Yi-Hsin
    Chu, Pao-Hsien
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (09): : 2493 - 2499
  • [42] Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes
    Khunti, K.
    Bellary, S.
    Karamat, M. A.
    Patel, K.
    Patel, V.
    Jones, A.
    Gray, J.
    Shepherd, P.
    Hanif, W.
    DIABETIC MEDICINE, 2017, 34 (01) : 64 - 68
  • [43] Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease
    SHamkhalova, M. S. H.
    YArek-Martynova, I. Y. A.
    Trubitsyna, N. P.
    SHestakova, M., V
    DIABETES MELLITUS, 2013, 16 (03): : 97 - 102
  • [44] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
    Rozalina G. McCoy
    Jeph Herrin
    Kavya Sindhu Swarna
    Yihong Deng
    David M. Kent
    Joseph S. Ross
    Guillermo E. Umpierrez
    Rodolfo J. Galindo
    William H. Crown
    Bijan J. Borah
    Victor M. Montori
    Juan P. Brito
    Joshua J. Neumiller
    Mindy M. Mickelson
    Eric C. Polley
    Nature Cardiovascular Research, 2024, 3 : 431 - 440
  • [45] Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLink™ Database
    Hoogwerf, Byron J.
    Pelletier, Elise M.
    Smith, Daniel B.
    Best, Jennie H.
    CIRCULATION, 2010, 122 (21)
  • [46] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
    Mccoy, Rozalina G.
    Herrin, Jeph
    Swarna, Kavya Sindhu
    Deng, Yihong
    Kent, David M.
    Ross, Joseph S.
    Umpierrez, Guillermo E.
    Galindo, Rodolfo J.
    Crown, William H.
    Borah, Bijan J.
    Montori, Victor M.
    Brito, Juan P.
    Neumiller, Joshua J.
    Mickelson, Mindy M.
    Polley, Eric C.
    NATURE CARDIOVASCULAR RESEARCH, 2024, 3 (04): : 431 - 440
  • [47] Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes
    Ray, Avik
    Paik, Julie M.
    Wexler, Deborah J.
    Sreedhara, Sushama K.
    Bykov, Katsiaryna
    Feldman, William B.
    Patorno, Elisabetta
    JAMA INTERNAL MEDICINE, 2025,
  • [48] Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes
    Morten Hansen
    David P. Sonne
    Filip K. Knop
    Current Diabetes Reports, 2014, 14
  • [49] COST-EFFECTIVENESS OF GLUCOSE-LOWERING THERAPIES AS ADD-ON TO STANDARD CARE FOR PEOPLE WITH TYPE 2 DIABETES IN MALAYSIA
    Sim, R.
    Chong, C. W.
    Loganadan, N. K.
    Adam, N. L.
    Hussein, Z.
    Lee, S. W. H.
    VALUE IN HEALTH, 2022, 25 (12) : S58 - S58
  • [50] Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes
    Hansen, Morten
    Sonne, David P.
    Knop, Filip K.
    CURRENT DIABETES REPORTS, 2014, 14 (05)
12345